Detalhe da pesquisa
1.
Preclinical toxicology profile of squalene epoxidase inhibitors.
Toxicol Appl Pharmacol
; 401: 115103, 2020 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32522582
2.
Exploration of cathepsin S inhibitors characterized by a triazole P1-P2 amide replacement.
Bioorg Med Chem Lett
; 22(23): 7189-93, 2012 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23084902
3.
Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Oral Ivosidenib in Otherwise Healthy Participants.
Clin Pharmacol Drug Dev
; 10(1): 99-109, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32648303
4.
Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP Deletion.
J Med Chem
; 64(8): 4430-4449, 2021 04 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33829783
5.
MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage.
Cancer Cell
; 39(2): 209-224.e11, 2021 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33450196
6.
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma.
ACS Med Chem Lett
; 11(2): 101-107, 2020 Feb 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-32071674
7.
A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties.
Bioorg Med Chem Lett
; 19(8): 2206-10, 2009 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19307114
8.
JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.
J Clin Invest
; 128(2): 789-804, 2018 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29355841
9.
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.
Cancer Discov
; 7(5): 478-493, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28193778
10.
JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.
J Clin Invest
; 128(10): 4743, 2018 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30222137